How big is the mycosis fungoides treatment market today, and what are its future growth expectations?
The mycosis fungoides treatment market size has grown strongly in recent years. It will grow from $0.97 billion in 2024 to $1.04 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increased incidences of immune system dysfunction, inflating utilization of efficacious therapeutics, widespread adoption of phototherapy, rise in usage of radiation therapy, and the increased popularity of supportive care measures.
The mycosis fungoides treatment market size is expected to see strong growth in the next few years. It will grow to $1.35 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to advancements in healthcare infrastructure, increasing patient population, and increase in prevalence of mycosis fungoides due to unhygienic lifestyles. Major trends in the forecast period include technological advancements in treatment associated with chemotherapy, a rise in demand for monoclonal antibodies as first-line therapy, the launch of new advanced products, and increasing investment in research and development.
Get Your Free Sample of The Global Mycosis Fungoides Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15613&type=smp
What are the top drivers to the rising demand in the mycosis fungoides treatment market?
The rise in lymphoma cancer incidence is expected to propel the growth of the mycosis fungoides treatment market going forward. Lymphoma refers to a cancer of the lymphatic system, which includes the lymph nodes, spleen, thymus gland, and bone marrow. Lymphoma cancer incidence is on the rise due to a combination of various factors, including environmental exposures, increasing viral infections, an aging population, and several lifestyle factors. Mycosis fungoides treatments, such as topical corticosteroids, phototherapy, and systemic therapies, are used in managing cutaneous T-cell lymphomas. These therapies aim to control skin lesions, reduce symptoms, and manage disease progression in lymphoma patients. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, non-Hodgkin lymphoma (NHL) was one of the most common cancers in the United States, accounting for about 4% of all cancers. It was estimated that approximately 80,620 people (44,590 males and 36,030 females) would be diagnosed with NHL, and about 20,140 people (11,780 males and 8,360 females) would die from this cancer in 2024. Therefore, the rise in lymphoma cancer incidence is driving the growth of the mycosis fungoides treatment market.
How is the mycosis fungoides treatment market segmented?
The mycosis fungoides treatment market covered in this report is segmented –
1) By Drug Type: Topical Steroids, Mechlorethamine
2) By Treatment Type: Photodynamic Therapy, Radiation Therapy, Targeted Therapy, Chemotherapy
3) By End-user: Hospitals, Private Clinics, Specialty Clinics
Subsegments:
1) By Topical Steroids: Corticosteroid Creams Or Ointments ( Hydrocortisone, Clobetasol), Topical Steroid Lotions
2) By Mechlorethamine: Topical Mechlorethamine ( Nitrogen Mustard Cream), Injectable Mechlorethamine
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/mycosis-fungoides-treatment-global-market-report
Who are the top competitors in the mycosis fungoides treatment market?
Major companies operating in the mycosis fungoides treatment market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Tocris Bioscience, Viatris Inc., Astellas Pharma Inc., Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Bausch Health, Eisai Co. Ltd., Horizon Therapeutics plc, Varian Medical Systems, Kyowa Kirin Co. Ltd., Seattle Genetics Inc., Azurity Pharmaceuticals Inc., Innate Pharma S.A., Helsinn Therapeutics, Jubilant Cadista Pharmaceuticals Inc., Elorac Inc., Soligenix Inc., Ceptaris Therapeutics Inc.
What significant trends should we anticipate in the mycosis fungoides treatment market over the forecast period?
Major companies operating in the mycosis fungoides treatment market are developing advanced therapies, such as CAR T cell therapy, to enhance the efficacy and specificity of treatments. CAR T cell therapy, or chimeric antigen receptor T cell therapy, is a type of immunotherapy that involves genetically engineering a patient’s own T cells to better recognize and attack cancer cells, including those associated with mycosis fungoides. For instance, in September 2022, CRISPR Therapeutics AG, a Switzerland-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the company’s wholly-owned allogeneic CAR T cell therapy targeting CD70, for treating Mycosis Fungoides and Sézary Syndrome (MF or SS). This designation is a significant milestone for the CTX130 program, recognizing the transformative potential of this cell therapy in patients with T-cell lymphomas based on promising clinical data. The RMAT designation is part of a dedicated program established under the 21st Century Cures Act to expedite drug development and review processes for genetic therapies intended to treat serious or life-threatening diseases.
Which regional trends are influencing the mycosis fungoides treatment market, and which area dominates the industry?
North America was the largest region in the mycosis fungoides treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mycosis fungoides treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Mycosis Fungoides Treatment Market Report 2025 Offer?
The mycosis fungoides treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Mycosis fungoides treatment refers to the use of various therapies, medications, and procedures to manage and alleviate the symptoms of a disease called cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma that primarily affects the skin. This treatment typically involves a combination of therapies, such as topical medications and systemic treatments like immunotherapy, depending on the stage and severity of the disease.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15613
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
